Disease | malignant glioma |
Phenotype | C0011334|cavities |
Sentences | 1 |
PubMedID- 22144871 | Zalutsky et al[44] investigated the use of 211at-labeled chimeric 81c6 antitenascin monoclonal antibodies administered to surgically created (tumor) resection cavities in patients with recurrent malignant gliomas. |
Page: 1